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Abstract 
Microemulsions combine the advantages of emulsions with those of nanocarriers, overcoming the stability problems 
of the former and providing facile scalable systems with compartments adequate for high drug loadings. Recently, 
microemulsions are gaining attention in the formulation of anticancer drugs not only for topical treatment, but also 
for systemic delivery as well as for the development of theranostic systems. The aim of this paper is two-fold. First, 
an updated review about general features, preparation, characterization and pharmaceutical applications, with a 
special focus on colorectal cancer, is provided. Second, a case study of formulation of methotrexate in 
microemulsions is presented. Various essential oils (menthol, trans-anethole, α-tocopherol) and surfactants (TPGS-
l000, Maxemul 6112, Noigen RN-20) were investigated for the preparation of o/w microemulsions for the delivery of 
methotrexate, and the ability of methotrexate-loaded microemulsions to inhibit cancer cell growth was then 
evaluated. Disregarding the surfactants used, menthol and trans-anethole led to cytotoxic microemulsions, whereas α-
tocopherol based-formulations induced cell proliferation. These findings highlight the role that the oily component 
may play in the efficacy and safety of the microemulsions. 
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1. Microemulsions  
1.1. General Issues  
Microemulsions are ternary systems comprising an aqueous phase, an oily phase and a relatively large 
proportion of amphiphilic compounds and co-surfactants (usually short aliphatic alcohols), which enable 
the obtaining of a single optically isotropic and thermodynamically stable liquid dispersion [1-3]. Mean 
size of inner phase globules is in l0 100 nm scale and, therefore, visible light is not dispersed when passes 
through microemulsions [4]. Unlike conventional emulsions, typical characteristics of microemulsions are 
the ultra low interfacial tension between the immiscible phases, lower input of energy for preparation, and 
higher thermodynamic stability (Table 1) [5]. There are also important differences between 
microemulsions and nanoemulsions (also named sub-micron emulsions); the latter are prepared from 
emulsions that are subjected to high shear stress or mechanical extrusion processes and are 
thermodynamically unstable [6].  
  
Table 1. Differences between microemulsions and emulsions [8] 
Property  Microemulsion Emulsion 
   
Appearance  Transparent/translucent Milky 
Thermodynamic stability Stable Unstable (kinetically stabilized) 
Formation  Spontaneous Energy input 
Interfacial tension  Towards 0 mNm-1 ~50 m N-1 
Microstructure  Dynamic (fluctuating surfaces) Static (until coalescence) 
Optical isotropy  Yes No 
Droplet size  10-100 nm >500 nm 
   
 
Combination of the above mentioned advantages while maintaining the capacity to solubilize 
hydrophobic drugs explains that microemulsions occupy a relevant position among other nanometric 
carriers [7, 8]. It should be noted that compared to conventional and reverse micelle systems, the inner 
compartment of microemulsion droplets is notably larger and so is its capability to host larger amounts of 
drugs and even therapeutic macromolecules.  
Depending on the ratios between the components, three main types of microemulsions can be 
prepared. When the content in water is large, microemulsions consist of small oil droplets surrounded by 
an interfacial film of both surfactant and co-surfactant molecules and dispersed in the aqueous phase (o/w 
microemulsions). Oppositely, if the content in water is low, the situation is reversed and the system 
consists of water droplets dispersed in oil (w/o microemulsions). Those systems that exhibit a gradual 
transition from o/w to w/o microemulsion are known as bicontinuous microemulsions [9]. Since the 
2000s, U-type microemulsions are receiving increasing attention [10]. These are highly water dilutable 
microemulsions that change progressively upon water addition from w/o to o/w without phase change 
[11].  
Droplets in the microemulsions can adopt spherical (o/w, w/o) or tubular morphologies, depending on 
the magnitude of the surfactant packing parameter, v/(ao lc), where v is the volume occupied by the 
hydrocarbon tail of the surfactant, a0 is the area of the polar head and lc is the length of the totally 
extended hydrocarbon chain of the surfactant [12-14]. In this mini-review, the focus will be on o/w 
microemulsions with spherical droplets. Following the concept of the packing parameter it is found that 
when a0 > v/lc, then an o/w microemulsion forms; if a0 < v/lc, then a w/o microemulsion is obtained, and 
if a0 ≈ v/lc, then a middle-phase (bicontinuous) microemulsion is the preferred structure [13].  
Microemulsion formation is a spontaneous process, as indicated by a negative Gibbs free energy of 
formation, ΔG. For microemulsions, the equation can be written as: 
 
ΔG = γΔA  TΔS 
 
where γ is the interfacial tension, ΔA the change in interfacial area during the formation process, ΔS the 
change in entropy and T is the temperature. Microemulsion formation is accompanied by a significant 
increase in the interfacial area, A. In as much as the interfacial tension γ decreases notably (but remains 
positive all the time), a negative free energy is attained when the interfacial energy (γA) is compensated 
by a dramatic change in the dispersion entropy of the system [15, 16]. A very low interfacial tension 
required for microemulsion formation cannot always be accomplished by the selected surfactant and 
sometimes a co- surfactant is required. The co-surfactant penetrates the amphiphilic interfacial layer, and 
increases its curvature and fluidity [16, 17]. For this purpose and for reasons of biocompatibility, 
preferably non-ionic surfactants and short or medium chain alcohol s are used [8, 15, 16].  
Phase equilibria in microemulsions can be studied through the construction of phase diagrams at a 
given temperature. In its simplest form, the diagram includes the proportions of oil, water and surfactant 
mixtures, and shows the combinations that lead to a single (apparent) phase [18]. A well-known 
classification of microemulsions is that of the Winsor type systems [19]. A Winsor I system consists of 
two phases, in which the o/w microemulsion phase placed at the bottom is in equilibrium with the 
supernatant oil in excess. Winsor II system comprises two phases also, but the upper microemulsion 
phase (w/o) is in equilibrium with excess water. Winsor III systems are characterized by the coexistence 
of three phases: the microemulsion (o/w plus w/o, also known as bicontinuous) located in between oil 
(upper phase) and water (lower phase). Winsor IV systems exhibit a single phase domain, with oil, water 
and surfactant homogeneously mixed (microemulsion). These systems are schematically represented in 
(Fig. 1).  
 
 
 
Fig. (l). Winsor classification of microemulsion systems [19].  
1.2. Microemulsions Preparation  
Preparation of a microemulsion to be used as drug nanocarrier system requires a careful selection of 
both qualitative and quantitative composition. The components should be chosen to fit the 
biocompatibility demands of the administration route and, therefore, adverse reactions and sensitizing or 
irritation potential of each compound have to be carefully considered. Moreover, the components should 
have adequate physicochemical properties, mainly regarding melting point, viscosity, chemical stability, 
ionization degree, and pH. On the other hand, the formation of thermodynamically stable microemulsions 
requires an adequate amount of the components to be mixed. As mentioned above, an important tool to 
correctly choose the compositions is the elaboration of ternary or pseudoternary phase diagrams.  
1.2.1. Components  
 
Oil phase. Most microemulsions performing as drug nanocarriers are o/w systems and, consequently, 
the main criterion that the oil phase must accomplish is that the drug should have high solubility in it. The 
oil also affects the curvature of the microemulsion droplet, as this depends on the ability of the surfactant 
tails to penetrate and swell in the interface. Since the drug delivery system should be biocompatible, 
excipients to be used in the formulation are restricted to some natural oils (com, cottonseed, orange, 
clove, peppermint, eucalyptol, coconut, soybean and jojoba oils) [20-24], triglycerides and esters of fatty 
acids (e.g., isopropyl myristate (IPM), ethyl oleate) [25-27].  
Aqueous phase. It usually contains regulators of pH (buffers) and ionic strength (salts) as well as 
certain cosolvents (mainly alcohols).  
1.2.1.1. Surfactants  
 
The role of the surfactant in the formulation is to lower the interfacial tension between oil and water as 
much as possible in order to facilitate the spontaneous formation of the microemulsion and to provide 
mechanical flexibility to the droplets. The surfactant should have the appropriate lipophilic character to 
give the correct curvature at the interfacial region. The emulsifying capability of an agent may be 
classified according to the hydrophilic-lipophilic balance (HLB) in its molecule. This is a function of the 
weight percentage of hydrophilic groups in the molecule [28]. Generally low HLB (< 12) surfactants lead 
to w/o microemulsions, while high HLB (> 12) ones are mostly suitable for o/w microemulsions. 
Commonly used surfactants are Aerosol OT and non-ionic molecules, such as polysorbates, alkyl 
polyethers, and sorbitan monoesters [29]. Surfactants are commonly included at proportions as high as 
25% and, therefore, they should be carefully chosen to avoid toxicity problems when administered 
through a given route. In general, surfactants cannot be assumed to be inert excipients since they can 
modify the transfer of drugs across biological membranes. Further, surfactants might produce significant 
changes in the biological activity of drugs by exerting an influence on metabolizing enzymes or on the 
binding to receptor proteins [30].  
1.2.1.2. Co-surfactants  
 
They are short to medium chain length alcohols or amines (C3-C8) that reduce the interfacial tension 
and increase the fluidity of the interface [29, 31]. Both surfactants and co-surfactants migrate to the 
liquid-liquid interface, which helps to decrease more the interface tension.  
1.2.1.3. Drugs  
 
Commonly the drug is incorporated to the inner oil phase, but if the drug is oily, it may constitute 
itself the inner phase. Hydrophilic drugs could be also dissolved in the aqueous phase, and the 
microemulsion could allow formulating together immiscible/incompatible drugs or may enable a rapid 
release of the drug from the aqueous phase and a sustained release of the drug incorporated into the oil 
phase.  
1.2.2. Preparation Methods  
 
There are two main methods to prepare microemulsions, as described below.  
1.2.2.1. Phase Titration Method  
 
First a ternary or pseudoternary diagram is constructed. Each comer represents 100% of a particular 
component, as shown in (Fig. 2). The regions can be separated into w/o or o/w microemulsions by simply 
considering whether it is oil rich or water rich. If only water and surfactant predominate, conventional 
micelles are formed. Oppositely, the surfactant molecules arrange in the form of reverse micelles if oil 
and surfactant are the major components.  
 
 
 
Fig. (2). Schematic phase diagram showing the regions where 
microemulsions are formed.  
  
1.2.2.2. Phase Inversion Method  
 
lt consists in increasing the temperature to cause loss of water of the head groups of the surfactants 
[32]. Shrinking the head group area of the non-ionic surfactant causes a phase inversion from o/w to w/o 
microemulsions in two-phase mixtures with either excess oil or excess water (phase inversion 
temperature, PIT) [33]. The changes in the curvature of non-ionic surfactant packing force a transition 
from an o/w microemulsion at low temperature to a w/o microemulsion at higher temperature (transitional 
phase inversion) [34]. Alternatively, phase inversion can occur adding the dispersed phase in excess. 
Phase inversion is accompanied by marked changes in physical properties including droplet size.  
1.3. Microemulsions Characterization  
The characterization of microemulsions is a difficult task due to their complexity and the variety of 
structures and components involved in these systems. The starting point is the construction of a ternary 
diagram (as depicted in Fig. 2). More complex and sophisticated techniques are then used to investigate in 
detail physicochemical properties and their dependence on the composition and variables such as pH or 
temperature. Some of the techniques most frequently used are electron microscopy, nuclear magnetic 
resonance, spectroscopy, rheology, electrical conductivity, and radiation scattering.  
Scattering techniques involve X-rays, neutrons and light and provide information about droplet size 
and internal structure. These techniques rely on the application of an incident beam of radiation to the 
sample, and subsequent registration of the intensity and the angle of the scattered beam. The scattering 
originates when the radiation interacts with regions of different refractive index (light scattering), electron 
density (X-ray scattering) or nuclear composition (neutron scattering) [18, 35]. Dynamic light scattering 
(DLS), quasielastic light scattering and photon correlation spectroscopy have been applied to analyze 
microemulsion droplet size via determination of the hydrodynamic radius, which can be estimated from 
measurements of the diffusion coefficients of the dispersed phase (droplets) undergoing Brownian 
motion. The equipment employed in this technique is rather simple and experimental times are very short 
[36, 37]. In the small-angle x-ray scattering (SAXS) technique, the scattering profile at low angles is 
fitted to adequate models to obtain reports about the shape, size and nanostructure of scattering elements; 
in the case of microemulsions, angles must be lower than 10, because of the scale of study is > 10 nm 
[18].  
Comprehensive information about characterization techniques can be found in recent reviews [18, 35] 
and the interested reader is referred to them for details.  
 
2. Microemulsions as drug delivery systems  
2.1. Application Field  
In the past 20 years, oil-in-water and water-in-oil microemulsions have been intensive1y evaluated as 
carriers for drug delivery [37]. Microemulsion systems allow sustained or controlled release of drugs for 
transdermal, topical, oral, nasal, ocular, parenteral and other administration routes [5]. The shelf-life of 
the microemulsions largely depends on their thermodynamic stability and the chemical stability of the 
drug in the dispersed phase. Stability in a wide range of temperatures, viscosity sufficiently low to allow 
filtration sterilization, acceptance of a variety of additives, removal from the application site or c1earance 
from the body are key factors for the use of these systems in the pharmaceutical field [38, 39]. Most 
research has focused on applications related to skin therapy and transdermal delivery [40, 41] due to 
concerns raised by the use of so large amounts of surfactants. Nevertheless, if the composition is 
adequately tuned, microemulsions can offer important advantages for systemic delivery of drugs.  
Since microemulsions possess both polar and non-polar microdomains, it is possible to solubilize both 
hydrophilic and lipophilic drugs in these microscopically heterogeneous but macroscopically 
homogeneous systems [27, 42-44]. Their large content in surfactants al so contributes to the solubilization 
capability of the microemulsions. In fact, microemulsions can increase up to several orders of magnitude 
the apparent solubility of drugs considered of Class II of the Biopharmaceutical Classification System 
(BCS), notably enhancing their oral bioavailability [20, 45, 46]. Encapsulation in the droplets also 
protects the drug from adverse environments, improving the stability against hydrolytic and oxidative 
processes. Additionally, since the small droplets can rapidly extend on epithelia (including the 
gastrointestinal one) and the surfactants can increase cell permeability, microemulsions have been shown 
to favor the permeability/absorption of a variety of drugs, inc1uding peptides and proteins [47]. 
Accumulation in intestinal lymph and absorption via the lymphatic route can also play a role in the oral 
absorption of drugs encapsulated in lipid droplets [48].  
Regarding parenteral delivery, o/w microemulsions have been largely tested as depots of hydrophobic 
drugs when administered subcutaneously or intramuscularly. A similar role can be played by w/o 
microemulsions encapsulating hydrophilic drugs. Intravenous administration of hydrophobic antitumoral, 
antimicrobial and antiinflamatory drugs has been shown to be also notably facilitated when formulated as 
o/w microemulsions [49]. Microemulsions enable the preparation of liquid formulations (with the drug 
totally solubilized in the droplets) avoiding the use of ethoxylated castor oil (Cremophor
®
 EL) which is 
commonly employed to prepare injectable solutions of hydrophobic therapeutic agents. Additionally, if 
PEGylated surfactants are used, microemulsions show high physical stability in plasma and great 
resistance to leaching of drugs through the oil phase, which in turn facilitates a sustained re1ease of the 
drug in the blood stream [50-52]. The small size of the microemulsion droplets ensures that the 
probability of emboli formation in the blood is insignificant and, if the surface is neutral or anionic, a 
prolonged blood circulation time can be achieved [49]. All together these features make microemulsions 
attractive for passive targeting of drugs towards tissues showing enhanced capillary permeability, such as 
those affected by inflammatory, infectious or tumoral processes. Sizes between 10 and 100 nm (which are 
the typical ones of microemulsion droplets) have been pointed out as the optimum for exploiting the 
enhanced permeability and retention (EPR) effect [53]. Selective extravasation of drug- loaded droplets 
can allow for greater accumulation of the drug in the sites of the body where it is required. Therefore, 
therapeutic efficacy is improved while total systemic dose can be notably diminished [5]. For example, 
phospholipid- based microemulsions loaded with all-trans-retinoic acid have been proved to be suitable 
for treatment of patients with acute promyelocytic leukemia [54]. Although much less investigated than 
other nanocarriers, microemulsion droplets could be al so susceptible of decoration with ligands able to 
recognize specific cells, enabling active targeting as recently demonstrated for nanoemulsions [55]. 
Moreover, microemulsions droplets are suitable starting cores for functionalization with diagnostic agents 
(magnetic resonance imaging (MRI), X-ray computed tomography (CT) imaging) and may lead to 
theranostic systems [56].  
Drug release rate from microemulsions largely depends on the composition of each specific 
formulation and on the environmental conditions (e.g., pH, stirring, ionic strength, enzymes). In o/w 
microemulsions, the oily droplets behave as cores and the lipophilic drugs have to cross the surfactant 
layer (which may behave as an additional, intermediate phase) and then diffuse towards the aqueous 
barrier and partition into it [57]. The strength of the interactions between microemulsion components has 
been shown to play a role in the release rate of ketoprofen and octylmethoxycinnamte [58, 59]. For drugs 
showing poor affinity for the aqueous environment, drug solubility in the aqueous phase may become the 
rate limiting step of the release process. If surfactant species are present in the release medium (as occurs 
when microemulsions are orally administered), interaction of the drug with the surfactants may also play 
a relevant role in the release process, and profiles typical of diffusion through a thick membrane can be 
obtained [60, 61]. Temperature has been shown to notably affect the release rate of Vitamins C and E 
from isopropyl myristate, Tween 80 and Imwitor 308 o/w microemulsions [62] and from isopropyl 
myristate, Span 20, Tween 20 microemulsions which also incorporated Pluronic FI27 in the aqueous 
phase [63].  
2.2. Microemulsions for Colorectal Cancer Treatments  
In the last two decades intensive research has been focused on the formulation of different anticancer 
drugs as microemulsions. Paclitaxel (PTX), methotrexate (MTX), curcumin (CUC), and doxorubicin 
(DOX) have been shown to be soluble in a variety of oils (essential and edible) and also to be 
incorporated with high encapsulation yield in microemulsions [64-76]. These systems have been tested in 
different cell lines such as breast, cervical, colon and colorectal cancer cells. In some reports it has been 
noted that blank microemulsions themselves have certain activity against the cancer cells. Thus, drug-
loaded microemulsions inhibit cell growth with lower dose of the chemotherapeutic agent. Relevant 
microemulsions loaded with anticancer drugs that have been successfully employed either in in vitro or in 
vivo studies are reported in Table 2.  
  
Table 2. Relevant microemulsion systems loaded with different drugs and tested in vitro or in vivo for the treatment of several types 
of cancer.  
Surfactant/Ce-surfactant  Oil phase Drug In vitro studies In vivo studies Ref. 
      
PEG-20 glycerol monooleate1 Pelemol© CUC - Human [64] 
Lecithin/butanol1 
Capmul1 
My vacet oil PTX MDA-M231 breast 
cancer cells 
 [65] 
Tween 80/isopropanol2 
Tween 80/propylenglycol2 
Isopropylmyristate 
Ethyl oleate 
Cynanine IR-768 Human red blood cells. 
MCF-7/WT and MCF-
7/DX breast cancer 
cells 
 [66] 
Tween 80/transcutol2  Capmul MCM Melphalan Human cervical 
(HeLa)cancer 
Mice [67] 
Lecithin/bencil alcohol1  Decanol MTX Hairless mouse skin - [68] 
Labrasol/Plurol isostearique2,4  Ethyl oleate MTX - Pig [69] 
Tween80/lecithin2,3  Soybean oil CUC Oral squamous cell 
(carcinoma cell lines) 
- [70] 
Cremophor EL/Transcutol2 Capryol 90 Docetaxel Caco 2 cells Rats [71] 
Cremophor EL/Span 
80/isopropyl alcohol1 
Corn oil MTX MCF-7 cellline, DU-
145 cell line and 
OVCAR cell line 
- [72] 
Polysorbate 80/capmul2  My vacet oil PTX lntestine rats Rats [73] 
Egg phosphatidylcholine 
Cremophor EL2 
Cremophor 
EL/pluronic 
F68/alcohol 
PTX - Hypersensivity (in pigs) 
and pharmacokinetic 
profile (in rats) 
[74] 
TPGS/lsopropyl alcohol2  IPM/Oleic acid Temozolomide acid 
hexyl ester 
Rat skin - [75] 
Soya phosphatidylcholine/ 
Eumulgin HRE 40/ sodium 
oleate2 
Cholesterol DOX - - [76] 
      
 
As can be seen in Table 2 most of the surfactants are quite biocompatible (e.g., polysorbates, soya 
derivatives and lecithin) and may partially or even totally replace Cremophor EL.  
Compared to other cancer cells, the studies about the use of microemulsions (loaded or non-loaded 
with anticancer drugs) for inhibiting the growth of colorectal cancer cells is much limited. Reports in the 
literature are still scarce. Microemulsions based on 37% Cremophor EL/transcutol mixture 2:1, 29% 
Capryol 90, and 34% water were loaded with docetaxel and tested in colon cancer cells (HCT-116), [77] 
Droplets without drug (blank microemulsion) had sizes in the 89±25 nm range, while after loading the 
size increased up to 205± 13 nm, All microemulsions showed high cytotoxic effects on colon cancer cells 
compared with the reference Taxotere, but caused less detrimental effects on non-tumoral human 
epithelial cells. Therefore, docetaxel-loaded microemulsions showed improved therapeutic efficacy and 
safety [78]. In other work, microemulsions were prepared combining Tween 80, Span 20, ethanol, 
isopropyl myristate and water and loaded with gemcitabine [78], a chemotherapeutic agent effective 
against many solid tumors and also employed in colorectal cancer treatment [79]. Drug-loaded 
microemulsions had high hemolysis activity (17-21 %) although below that exhibited by a drug solution 
of similar concentration (37%). Blank microemulsions showed a relevant cytotoxic activity (30-50% 
growth inhibition) against HCT-116 colon cancer cells. Moreover, cells treated with drug-loaded 
microemulsions showed more intense apoptosis than those exposed to the drug solution [78].  
  
Microemulsions have been also shown to be particularly suitable to encapsulate plant extracts whose 
antitumoral activity is limited by a poor aqueous solubility [80, 81]. For example, Flammulina velutipes 
sterol (active against gastric and colon cancer cells) was encapsulated in a microemulsion prepared with 
0.3% medium chain triglycerides, 5.0% ethanol, 21.0% Cremophor EL and 71.0% water, leading to an 
apparent solubility of the sterol of three orders of magnitude higher with respect to the solubility in water 
[80]. lnterestingly, the microemulsion exhibited a good physical stability and no loss of drug was 
observed in the first 24 hours after 100-fold dilution with distilled water. When orally administered to 
healthy rats, microemulsions increased more than 2-fold the bioavailability of the sterol. Similarly, 
quercetin was formulated in a microemulsion prepared with 7% ethyl oleate, 48% Tween 80 and 45% 
dehydrated ethanol (co-surfactant) [82]. Compared to quercertin-loaded micelles (without ethyl oleate), 
the microemulsion notably enhanced intestinal absorption of the drug. lnterestingly, site-specific 
absorption of the drug- loaded emulsion was observed in vivo; the uptake percentage being greater in 
colon followed by ileum. These findings can be related to the thinner mucous layer of the colon and to the 
predominance of M cells and lymphatic vessels of ileum.  
3. Formulation of methotrexate microemulsions  
In the last part of this paper, a case study of formulation of MTX in microemulsions is presented. The 
aim was to investigate the suitability of essential oils for the preparation of o/w microemulsions for the 
delivery of methotrexate and to elucidate the ability to inhibit cancer cell growth.  
3.1. Materials  
Balb 3T3 done A31 mouse embryonic fibroblast cells (CCL-163) and HeLa cervical cancer cells 
(CCL-2) from American Type Culture Collection (USA). DMEM F12-HAM, RPMI 1640 with and 
without folic acid, D-α- tocopherol polyethylene glycol 1000 succinate (TPGS- 1000), 2-methyl-1-
propanol (isobutanol), D-L-α-tocopherol (vitamin E) and trans-anethole from Sigma-Aldrich (Germany); 
mentha piperita (peppermint) essential oil (menthol main component) from Eladiet (Spain); penicillin/ 
streptomycin from Hyclone Thermo Scientific (UK), fetal bovine serum (FBS) from Biowest (France), 
Maxemul 6112 from Croda (UK), Noigen RN-20 from Dai-Ichi Kogyo Seiyaku (Japan), methotrexate 
(MTX) from AK Scientific (USA), and MTT proliferation Kit from Roche (Germany). Ultrapure MilliQ 
water was obtained using a Millipore equipment (Spain). Other reagents were analytical grade.  
3.2. Methods  
3.2.1. Preparation of'o/w Microemutsions  
 
Solutions of Maxemul 6112 (10% w/w; anionic surfactant) and TPGS-1000 (10% w/w; non-ionic 
surfactant) were prepared separately in phosphate buffer pH 7.4 (PBS). Then, isobutanol was added 
dropwise and magnetic stirring was maintained until the solutions became transparent again. In the case 
of MTX-loaded microemulsions, fue drug was first dissolved in isobutanol. Following, oil phase was 
added (compositions in Table 3) and the systems were kept under magnetic stirring until the turbidity 
disappeared. MTX final concentration was 0.3 mg/mL in microemulsions prepared with D-L-α-
tocopherol (vitamin E) and 0.6 mg/mL in microemulsions with trans-anethole or menthol. Additionally, 
mixtures (50/50 w/w) of Maxemul 6112 and Noigen RN-20 (non-ionic surfactant) with TPGS-1000 were 
also tested to prepare the microemulsions.  
  
Table 3. Composition of microemulsions (in percentage in the final formulation). MTX-loaded microemulsions were identified with 
the same codes as placebo but ending in b (e.g., l3b, 14b, 15b, 16b, 17b, 1 9b, 20b, 21 b, 22b, 23b, 24b 
Code PBS TPGS-1000 
Maxemul 
6112 
Noigen  
RN-20 
lsobutanol Menthol 
Trans- 
anethole 
α- Tocopherol 
         
13 81.60 9.07 --- --- 8.61 0.73 -- --- 
14 79.89 8.98 --- --- 8.43 2.80 -- --- 
15 80.68 8.96 --- --- 8.52 --- -- 1.79 
16 81.73 8.17 --- 0.91 8.63 0.56 -- --- 
17 79.47 7.95 --- 0.88 8.39 --- 3.31 --- 
19 79.89 --- 8.88 --- 8.43 2.80 --- --- 
20 81.10 --- 9.01 --- 8.56 --- 1.33 --- 
21 80.34 --- 8.93 --- 8.48 --- -- 2.26 
22 81.71 4.54 4.54 --- 8.62 0.54 -- --- 
23 81.01 4.50 4.50 --- 8.55 --- 1.44 --- 
24 80.35 4.46 4.46 --- 8.48 --- -- 2.21 
         
 
3.2.2. Proliferation Cell Assay  
 
Balb 3T3 were cultured in DMEM F12-HAM medium containing 10% FBS and 1% penicillin (10,000 
units/mL)/ streptomycin (10,000 ug/ml.) solution, and HeLa cells were cultured in RPMI 1640 medium 
supplemented with 10% FBS and 1 % antibiotics solution. Both cell lines were seeded in 96-well plates at 
a density of 200,000 cells/mL (100 µL) in RPMI 1640 without folic acid and supplemented with 10% 
FBS and 1 % antibiotics solution, and incubated for 24 hours at 37°C, 5% CO2 and 90% relative 
humidity. Aliquots of microemulsions (100 µL) were added to each well. Plates were incubated during 24 
and 48 hours. All experiments were carried out in triplicate.  
Components of the microemulsions were separately dispersed phosphate buffered saline (PBS, Sigma-
Aldrich) and tested at the same concentration as in the formulations. To do that, 2 µl of component 
dispersion was added to each well and incubated as indicated above. After 24 and 48 h of exposition, cell 
proliferation was measured using a MTT Kit (Roche, Gennany), following the manufacturer instructions. 
Absorbance was measured at a wavelength of 550 nm using an ELISA plate reader (BJORAD Model 680 
Microplate Reader, USA). 
3.3. Results and Discussion  
3.3.1. Preparation of microemulsions  
 
Several essential oils were investigated for the preparation of MTX-loaded o/w microemulsions. 
Peppermint oil (having menthol as main component) has been tested in the preparation of microemulsions 
[83, 84] loaded with celecoxib [85] or other anti-inflammatory drugs such as aceclofenac and diclofenac 
[86]. On the other hand, trans-anethole (1-methoxy-4-(l E)-1-propenylbenzene) is the major component 
(>99 %) of the naturally occurring essential oils of fennel and star anise, and is also present in dill, basil, 
and tarragon plants. It is widely used as an aniseed flavoring agent in a variety of confectioneries and 
beverages. Also, it has been used as an important ingredient of herbal medicines for centuries. Further, it 
has been shown that 1 mM trans-anethole causes death of MCF-7 human breast cancer cells after three 
days exposition [87]. Just recently, liposomal formulations of trans-anethole have been reported to be 
eight to nine times more cytotoxic than free trans- anethole in T47D and MCF-7 breast cancer cell lines. 
Therefore, the use of trans-anethole as oil carrier of antineoplastic agents may strengthen the cytotoxic 
effects. Finally, a -tocopherol and its derivatives have been pointed out to also have antitumor and anti-
inflammatory activity [88].  
TPGS-1000 is a biocompatible surfactant widely used as solubilizer and emulsifier. It may provide 
microemulsion droplets with prolonged circulation half-life and improved tumor accumulation, as 
previously observed for related surfactants such as distearoylphosphatidylethanolamine (DSPE)-PEG 
2000 or 5000 [89]. Furthermore, it has been reported that TPGS inhibits P-glycoprotein efflux pump 
increasing oral absorption and cell accumulation of a variety of drugs, including antitumoral drugs [90-
92]. Other surfactant tested was Maxemul 6112, an anionic phosphate ester (oleyl alcohol ethoxylate 
phosphate, concentration between 50 and 100 % w/w) with a polymerizable double bond in its main 
hydrocarbon chain, which may allow to form a stimuli responsive polymeric shell coating the drug- 
loaded oleic core. Similarly Noigen RN-20 (polyoxyethylene 4-nonyl-2-propylene-phenol) is a nonionic 
polymerizable surfactant (HLB 15.4), which has been previously shown useful for the stabilization of 
non-aqueous emulsions [93].  
As a first step, the phase diagrams of ternary systems combining each essential oil, water and a 
mixture of TPGS- 1000 (surfactant) and isobutanol (co-surfactant) were obtained (Fig. 3). For the three 
essential oils tested, proportions of surfactant and co-surfactant above 10% were required. 
Microemulsions with peppermint oil (menthol) only formed when the oil was at very low proportion, 
which may represent a limitation for the incorporation of hydrophobic drugs. Microemulsions prepared 
with the compositions disclosed in Table 3 were proven to be transparent and homogeneous. Drug-loaded 
formulations were yellow due to drug color.  
 
 
 
Fig. (3). Partial phase diagrams of ternary systems combining 
an essential oil, water and a mixture of TPGS-1000 (surfactant) 
and isobutanol (iso-BuOH, co-surfactant).  
  
3.3.2. Proliferation Cell Assay  
 
Microemulsions were tested regarding cytocompatibility using murine fibroblasts (Balb 3T3 cells), 
and regarding bioactivity using adenocarnicoma cells (HeLa cells) (Fig. 4). In the case of fibroblast cells, 
drug loaded and non-loaded microemulsions prepared with a -tocopherol significantly increased cell 
proliferation, both in the tests carried out with 100 µl of microemulsion. Formulations with menthol and 
trans-anethole proved to be less cytocompatible, as expected from the previously reported data about 
cytotoxicity of these essential oils [87]. No relevant differences were observed between microemulsions 
with and without MTX. As observed with fibroblast cells, microemulsions were bioactive against tumor 
cells except those prepared with α- tocopherol. Interestingly, menthol and trans-anethole microemulsions 
led to similar cytotoxicity leve\s.  
 
 
 
Fig. (4). Proliferation (in percentage) of murine fibroblasts (Balb 3T3 
cells) and adenocamicoma cells (HeLa cells) after 24 and 48 hours of 
incubation with 100 µl, of each microemulsion. Codes with "b" refer 
to MTX loaded formulations (compositions in Table 3). Blue, yellow 
and red bars identify microemulsions baving mentbol, α-tocopherol or 
trans-anethole as oily pbase, respectively.  
To gain further insight into the origin of the cytotoxic effects of the microemulsions, each component 
was tested in separate at the same concentration as it is present in the formulations. Isolated surfactants, 
particularly TPGS and Maxemul, were found to be extreme\y toxic for both fibroblasts and tumor cells 
(Fig. 5). It is known that surfactants exhibit concentration-dependent effects on cell viability and, in the 
absence of oils, TPGS and Maxemul unimers and micelles can readily interact with cell membranes and 
intracellular enzymes [94]. According to the suppliers, the oral LD50 (for rats) values of TPGS-I000, 
Maxemul 6112 and Noigen RN-20 are >7000, 1530 and 2500 mg/kg, respectively. Menthol and trans-
anethole led to detrimental effects on fibroblast viability after 48 h of incubation, but these essential oils 
did not significantly alter the viability of tumor cells. As expected, n-tocopherol showed an excellent 
cytocompatibility with fibroblasts and tumor cells. The proliferative effect of n-tocopherol explains its 
capability to counteract the toxicity of the surfactants.  
 
 
 
Fig. (5). Proliferation (in percentage) of Balb 3T3 cells and HeLa cells after 24 and 48 hours of 
incubation with each microemulsion component (2 µL dispersion in PBS) in separate.  
4. Conclusions  
Although the literature on microemulsions as carriers of antitumor agents is still incipient, recent 
papers have pointed out their suitability not only for topical or mucosal application but also for systemic 
delivery. Versatile preparation, high drug loading and droplet size adequate for drug targeting are the 
most relevant advantages of microemulsíons compared to other nanocarriers. However, concerns about 
the toxicity of the surfactants still prevent from the systemic use. The MTX formulation study points out 
that in addition to surfactants, the essential oils used as internal phase of o/w microemulsions may notably 
determine the cytocompatibility. Blank microemulsions prepared with menthol and trans-anethole inhibit 
cell proliferation as much as those loaded with methotrexate. By contrast, n-tocopherol leads to 
microemulsions that strongly promote proliferation of both fibroblasts and adenocarcinoma cells, being 
totally inadequate for cancer treatment. Therefore, much research is still required for identifying suitable 
oily components that enable a good balance between compatibility with healthy cells and growth 
inhibition of cancer cells.  
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